1. PTC Therapeutics will report Q4 and annual 2024 results on Feb. 27. 2. The call will provide updates on business outlook and financial performance. 3. Investors can access the call via a provided registration link. 4. PTC focuses on rare disorders with a diversified pipeline of medicines.
Earnings calls traditionally have limited immediate market impact unless expectations are significantly exceeded or missed. Past earnings calls for biopharma firms generally result in volatility only if guidance changes.
The earnings call could provide crucial updates, impacting investors' sentiment and stock position. However, without significant news or results, the impact is moderate.
Upcoming earnings report could influence short-term trading based on results. Similar past events have shown immediate reactions to quarterly results.
WARREN, N.J., Feb. 13, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2024 financial results and provide an update on the company's business and outlook on Thursday, Feb. 27, at 4:30 p.m. EST.
To access the call by phone, please click here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days.
PTC is a global biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, Instagram, LinkedIn, and X.
Investors: Ellen Cavaleri
+1 (615) 618-6228
[email protected]
Media: Jeanine Clemente
+1 (908) 912-9406
[email protected]
SOURCE PTC Therapeutics, Inc.